4.7 Article

Progress in the Development and Application of Small Molecule Inhibitors of Bromodomain-Acetyl-lysine Interactions

期刊

JOURNAL OF MEDICINAL CHEMISTRY
卷 55, 期 22, 页码 9393-9413

出版社

AMER CHEMICAL SOC
DOI: 10.1021/jm300915b

关键词

-

资金

  1. Cancer Research UK
  2. GlaxoSmithKline
  3. Pfizer Neusentis
  4. UCB
  5. Structural Genomics Consortium [1097737]
  6. Canadian Institutes for Health Research
  7. Canada Foundation for Innovation
  8. Genome Canada
  9. Pfizer
  10. Eli Lilly
  11. Novartis Research Foundation
  12. Ontario Ministry of Research and Innovation
  13. Wellcome Trust
  14. Cancer Research UK [6947] Funding Source: researchfish

向作者/读者索取更多资源

Bromodomains, protein modules that recognize and bind to acetylated lysine, are emerging as important components of cellular machinery. These acetyl-lysine (KAc) reader domains are part of the write-read-erase concept that has been linked with the transfer of epigenetic information. By reading KAc marks on histones, bromodomains mediate protein-protein interactions between a diverse array of partners. There has been intense activity in developing potent and selective small molecule probes that disrupt the interaction between a given bromodomain and KAc. Rapid success has been achieved with the BET family of bromodomains, and a number of potent and selective probes have been reported. These compounds have enabled linking of the BET bromodomains with diseases, including cancer and inflammation, suggesting that bromodomains are druggable targets. Herein, we review the biology of the bromodomains and discuss the SAR for the existing small molecule probes. The biology that has been enabled by these compounds is summarized.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据